This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Xuebijing injection (XBJ) and sepsis (septicaemia)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Xuebijing injection (XBJ) and sepsis (septicaemia)

  • an herbal-based intravenous preparation, was licensed in 2004 by the National Medical Products Administration (NMPA, China) for the treatment of sepsis and multiple organ dysfunction syndrome

  • Xuebijing injection (XBJ)
    • possesses an array of activities associated with its mechanism of protection in sepsis
    • can exert an antagonistic effect on endotoxin
    • an inhibitory effect on the uncontrolled release of endogenous inflammatory mediators produced by endotoxin-stimulated monocytes/macrophages
    • can improve the coagulation disorders present in disseminated intravascular coagulation

  • in this randomized clinical trial that included 1817 patients with sepsis, the 28-day mortality rate was 18.8% in the XBJ group vs 26.1% in the placebo group, a significant difference (1):
    • among patients with sepsis, treatment with XBJ, compared with the placebo group, resulted in lower 28-day mortality

Reference:

  • Liu S, Yao C, Xie J, et al. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial. JAMA Intern Med. Published online May 01, 2023. doi:10.1001/jamainternmed.2023.0780

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.